Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors73

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors15

Views

Views
October 20252
November 20256
December 20252
January 20261
February 20260
March 20264
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
Brazil3
France2
Argentina2
United Kingdom1
Mexico1
Paraguay1
 

Top cities views

Views
Rosario2
Porto Alegre2
Ashburn1
Asunción1
Atlanta1
Bauru1
Des Moines1
Xalapa1